Biosino Bio-Technology and Science Incorporation provided unaudited consolidated earnings guidance for the year ended 31 December 2023. for the year, Group is expected to record a net loss within a range of RMB 18,000,000 to RMB 22,000,000 for the Reporting Period as compared to a net profit of approximately RMB 14,202,000 for the year ended 31 December 2022. The Board considers that the expected loss for the Reporting Period is mainly attributable to (i) a decrease in the Group's gross profit due to (a) a drop in market demand as affected by changes in public health prevention and control policies both domestically and abroad; and (b) a drop in price of products as affected by industry centralised procurement; and (ii) an increase in the Group's research and development expenses on the its advantageous products, such as flow cytometry and supporting reagents.
Biosino Bio-Technology and Science Incorporation
Equities
8247
CNE100000288
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9 HKD | 0.00% | -2.17% | +12.50% |
1st Jan change | Capi. | |
---|---|---|
+12.50% | 16.65M | |
-1.49% | 12.71B | |
+0.13% | 8.37B | |
-1.12% | 5.4B | |
+20.18% | 5.27B | |
-0.74% | 4.63B | |
-54.68% | 3.13B | |
+24.56% | 2.77B | |
-8.47% | 2.25B | |
-1.86% | 1.95B |
- Stock Market
- Equities
- 8247 Stock
- News Biosino Bio-Technology and Science Incorporation
- Biosino Bio-Technology and Science Incorporation Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2023